Polycystic ovary syndrome — indication assessment

§1Assessment

§1.1Definition

A reproductive-endocrine disorder defined by combinations of ovulatory dysfunction, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology.

§1.2Anchor and additional outcomes

The Institute designates one anchor outcome per indication so that estimates for different compounds are reported on a common measure. The anchor for this indication is the first outcome below.

1. Change in body weight
2. Menstrual cyclicity
3. Change in free androgen index
4. Change in HOMA-IR
5. Ovulation and live-birth rate

§1.3State of the evidence

The Institute assesses 2 compounds in this indication, drawing on 0 trial records and 0 evidence syntheses. ^[1,2]

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089
2. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research 2010;27(4):544–575. doi:10.1007/s11095-009-0045-6 · PMID 20143256

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.